/ Print /

IN THE PIPELINE

Glaucoma monitoring implant receives CE markAn implantable glaucoma sensor has received CE mark approval for marketing in the European Union. The sensor (Eyemate, Implandata Ophthalmic Products) can provide frequent IOP readings, informing patients and their physicians about how the pressure changes by time of day and from one day to another.
FDA approves first generic Truvada for HIVThe first generic Truvada for treating and preventing HIV will be available, but when?
FDA gives once-daily HIV therapy go-aheadFDA approves Isentress at a higher dose for HIV-1 infected patients.
Asthma biologic may reduce oral steroid useA new trial for AstraZeneca’s benralizumab shows promising results for severe asthma patients.
First generic Strattera for ADHD approvedFDA has approved the first generic versions of Strattera (atomoxetine) for the treatment of attention deficit/hyperactivity disorder.
Investigational drug appears beneficial in preventing migrainesLilly's galcanezumab proves successful in three phase 3 migraine studies. Here are the findings.
Drugmaker recalls samples of antiplatelet drugAstraZeneca voluntarily recalls professional samples of its antiplatelet agent. Here's what to do.
Combination pack approved for breast cancer treatmentFDA approves ribociclib plus letrozole to treat a subset of advanced breast cancer patients.
Top 5 specialty drug management issuesThe 13th edition EMD Serono Specialty Digest outlines top specialty drug management issues health plans face.
How pharma reps impact physician prescribingA new study led by The University of California researchers and published in JAMA reveals surprising findings.